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Abstract
The aim. To clarify all most important immunohistochemical features of gastrointestinal stromal tumors with different 
histological patterns and analyze the role of expression of Ki-67, MMP-9, VEGF and p16ink4A as a predictive markers of tumor 
progression. 
Materials and methods. The study is based on analysis of 100 primary GISTs for description of their morphological features 
and 36 GISTs taken from this 100 for study of prognostic markers. 
Results. All spindle cell GISTs have shown diffuse expression of CD117 in tumor cells. The levels of CD117 expression va-
ried from strong expression (3+) until mild expression (1+). Strong expression were seen in 75.8 % of spindle cell GISTs. Epithelioid 
GISTs demonstrated heterognous moderate or mild expression of CD117. All primary epithelioid GISTs from patients that had relapse 
of tumor in period from 1 till 3 years demonstrated focal mild expression of CD 117 in tumor cells. Expression of DOG-1 were seen 
in all 100 cases of GISTs, that were included in our study. The strong expression of DOG-1 (3+) were seen in all 45 GISTs that had 
low mitotic rate (≤ 5 mitoses per 50HPF) and not associated with their histological pattern. GISTs with high mitotic rate demonstrated 
heterogeneous expression of DOG-1 in tumors: moderate expression (2+) with patchy areas of strong expression (3+). Expression of 
CD56 was not found in spindle cell GISTs, but single tumor cells of epithelioid GISTs that had high mitotic rate demonstrated ex-
pression of this marker. The average expression of p16ink4A were higher in tumors that gave relapses compared with tumors without 
relapses (50.3 % versus 5.7 % respectively, U-test = 16.5; p ≤ 0.01). The average expression of MMP-9 also were significantly higher 
in GISTs that gave relapses: 63.2 % compared with 13.4 % in GISTs without relapse (U-test = 16; p ≤ 0.01). The strong VEGF expres-
sion was found in 66.7 % of GISTs that had relapses and only in 8.3 % of GISTs without relapses. 50 % of GISTs without relapses 
was negative for VEGF. Finally, the average expression of Ki-67 were 13.4 % in GISTs with relapses and 8.7 % in GISTs without 
them (U-test = 16; p ≤ 0.01).
Conclusion. We highly recommend using DOG-1 for epithelioid GISTs. Additionally in epithelioid GISTs can be used CD56 
that can give focal positive reaction in some tumour cells. The following minimal panel of markers for differential diagnosis of 
spindled GISTs from other mesenchymal tumors of gastrointestinal tract is proposed: CD117, DOG-1 and SMA, where the first too 
markers will demonstrated the moderate or strong diffuse expression and SMA can be occasionally positive in some tumor cells. 
p16ink4A, Ki-67, VEGF and MMP-9 can be used as additional prognostic markers in GISTs.
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1. Introduction
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of di-
gestive system [1, 2]. The correct determination of these tumors are crucial for choosing the best 
strategy of treatment and prediction of tumor behavior. GISTs can share 2 most common histologi-
cal patterns: spindle cell morphology and epithelioid type. Nowadays the diagnosis GIST is not 
be full without immunohistochemical (IHC) testing with CD117 and/or DOG-1 [3, 4]. The spin-
dled GISTs should be differentiated from leiomyomas and schwannomas. Epithelioid GISTs are 
required differential diagnosis with huge specter of round cell tumors, starting from carcinoids and 
finishing with glomus tumors of stomach [5, 6]. GISTs have variable behavior; many of them are 
characterized by indolent course. However, at the same time, there are too less histological criteria, 
that allow to predict progression of GISTs. Criteria that were used in last histological classification 
of digestive system tumors include mitotic rate, tumor size and tumor site of location and only 
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1st criterion in this list is histological [1, 2, 7]. The IHC marker, such as widely used in different 
type of malignancies for analysis of their aggressiveness can be also used in GISTs as additional 
markers for prognosis of tumor behavior. The most popular markers from this group are Ki-67 
for evaluation of proliferative activity [8], MMP-9 that helps to check the ability of a tumor to 
invasion [9] and VEGF – the marker of angiogenesis [10]. P16ink4a is a particularly potent ef-
fector of cell cycle progression that functions in concert with CDK4/Cyclin D and RB in coordi-
nating proliferation. Application of immunohistochemical analysis with p16ink4A can be used as 
a novel biomarker for the detection of cancer cells in early stages [11]. 
The scientific papers that give complex study of immunohistochemical features of GISTs 
and analyze the markers of tumor aggressive behavior in groups with and without relapses are al-
most absent or they describe only couples of markers.
The aim of this study was to clarify all most important immunohistochemical features of 
gastrointestinal stromal tumors with different histological patterns and analyze the role of expres-
sion of Ki-67, MMP-9, VEGF and p16ink4A as a predictive markers of tumor progression. 
2. Material and methods
The study was performed on formalin fixed and paraffin embedded (FFPE) tumor samples 
of GISTs. The material included tumor samples of primary GISTs obtained from 100 patients, who 
have undergone surgical excision of tumors. Postoperative tumor material was obtained from pa-
thology departments of «Grigoriev Institute for Medical Radiology and Oncology of the National 
Academy of Medical Sciences of Ukraine», «V. T. Zaycev Institute of General and Urgent Surgery 
of NAMS of Ukraine» Kharkiv, Ukraine and «National Cancer Institute», Kyiv, Ukraine. All sur-
gical resections were performed between 2013 and 2019. 
The design of the study and all the methods used in the study were approved by the Bioethics 
Committee of the Kharkiv medical academy of postgraduate education, protocol 9 (21.11.2018) and 
complied with the requirements of the Declaration of Helsinki. Such clinic-morphological criteria 
as gender, site of tumor and its size were obtained from case histories, where we analyzed surgical 
protocols, data about chemotherapy and data from histological conclusions.
Eligibility criteria included the availability of follow-up data at least for a year after surgi-
cal resection of primary tumor positive immunohistochemical staining with CD117 and DOG-1 
confirming diagnosis GIST, presence of information about staining with SMA or available blocks 
with tumors with sufficient material for at least 4 histological sections. Additionally, we made IHC 
testing with CD34, CD56, SMA, DOG-1 if it was not performed previously. The information of 
100 cases of GISTs is given in Table 1.
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For ancillary study with markers of tumor aggressive behaviour (Ki-67, p16ink4A, VEGF 
and MMP-9) we choose 36 GISTs from 100 cases that have enough amount and good quality of 
material in formalin fixed and paraffin embedded (FFPE) tissue samples. Among 36 GISTs that 
we have chosen 12 had relapses in period from 1 till 3 years and 24 patients were without relapses 
in the same time lap. The characteristics of antibodies are given in Table 2. The whole study was 
performed according to the Dako protocol for manual IHC staining.
Table 2
List of primary antibodies used in our study
Primary antibody Clone Dilution Manufacturer
DOG-1 SP31 1:100 ThermoFisher Scientific, USA
CD117 A4502 1:250 Dako, Denmark
SMA 1A4 1:300 ThermoFisher Scientific, USA
СD34 QBEnd/10 1:500 ThermoFisher Scientific, USA
CD56 123С3 1:100
MMP-9 Ab-1 GE-213 1:200 ThermoFisher Scientific, USA
Ki-67 SP6 1:400 ThermoFisher Scientific, USA
VEGF JH121 1:20 ThermoFisher Scientific, USA
P16ink4A 1D7D2 1:200 ThermoFisher Scientific, USA
Quantitative method was used for evaluation of Ki-67, MMP-9 and p16ink4A expression.
Expression of p16ink4A was calculated as the percentage of the number of immunoposi-
tive cells (positive cytoplasmic staining with or without nuclear staining) among the total number 
of tumour cells in three areas of most intensive staining (in cases of heterogeneous expression) 
at ×400 magnification.
The semiquantitative approach was used for the assessment of VEGF, DOG-1, CD117, 
SMA, CD34 and CD56 and expression. 
Results were visualized and photographed using light microscope (ZEISS Primo Star, 
ZEISS Axiocam ERc5).
The Mann-Whitney U test was used to compare differences between expression of markers in 
group of GISTs with relapses in period from 1 till 3 years after surgery and without them in this time 
lap (P-value < 0.01). An extensive parameter (%) was used to describe qualitative characteristics. 
All statistical analyses were performed using «Microsoft Excel 2013» and «MedCalc».
3. Results
All spindle cell GISTs have shown diffuse expression of CD117 in tumour cells. The levels 
of CD117 expression varied from strong expression (3+) until mild expression (1+). Strong expres-
sion were seen in 75.8 % of spindle cell GISTs (Fig. 1). 
Mild expression of CD 117 in our study were more typical for tumors with mitotic rate higher 
that 5 mitoses per 50HPF (among 9 tumors with mild CD117 expression, 6 tumors had mitotic rate 
higher that 5 mitoses per 50HPF). Moreover, tumors with mild expression of CD117 had usually stro-
ma with areas of mixomatosis and small necrosis. Epithelioid GISTs demonstrated heterognous mode-
rate or mild expression of CD117. All primary epithelioid GISTs from patients that had relapse of tu-
mor in period from 1 till 3 years demonstrated focal mild expression of CD 117 in tumor cells (Fig. 2).
Expression of DOG-1 were seen in all 100 cases of GISTs, that were included in our study. 
The strong expression of DOG-1 (3+) were seen in all 45 GISTs that had low mitotic rate (≤ 5 mi-
toses per 50HPF) and not associated with their histological pattern. GISTs with high mitotic rate 
demonstrated heterogenous expression of DOG-1 in tumors: moderate expression (2+) with patchy 
areas of strong expression (3+).
All epithelioid GISTs in our study were negative for CD34. The spindle cell GISTs have 
shown next levels of CD34 expression: 35.2 % (32 samples) of tumors had strong expression of CD34, 
32.9 % (30 samples) – moderate expression and 31.9 % (29 samples) negative expression in tumor cells.
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Fig. 1. Expression of CD117 in spindle cell GISTs
Fig. 2. Mild to moderate focal expression of CD 117 in epithelioid GIST, ×1000
Expression of SMA was not detected in epithelioid GISTs, but in spindle cell GISTs occa-
sional expression of SMA in single tumor cells were seen in 13.2 % of cases.
Expression of CD56 was not found in spindle cell GISTs, but single tumor cells of epithelioid 
GISTs that had high mitotic rate demonstrated expression of this marker (Fig. 3).
Fig. 3. Expression of CD 56 in single tumor cells of epithelioid GIST, ×1000
Among 100 primary GISTs in our study we have only 3 tumors with mixed histological pattern. 
All these tumors have shown moderate expression of CD117 and strong expression of DOG-1.
The analysis of expression of IHC markers of tumor aggressive behavior such as p16ink4A, 
MMP-9, VEGF and ki-67 were performed on 36 cases of GISTs that were taken from our primary 
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100 cases. The relapse of tumor in period from 1 till 3 years were seen in 33.3 % of cases (12 pa-
tients) and other 66.7 % of cases did not develop relapse in mentioned time lap. 
The average expression of p16ink4A were higher in tumors that gave relapses compared 
with tumors without relapses (50.3 % versus 5.7 % respectively, U-test = 16.5; p ≤ 0.01).
The average expression of MMP-9 also were significantly higher in GISTs that gave relapses: 
63.2 % compared with 13.4 % in GISTs without relapse (U-test = 16; p ≤ 0.01).
The strong VEGF expression was found in 66.7 % of GISTs that had relapses and only in 
8.3 % of GISTs without relapses. 50 % of GISTs without relapses was negative for VEGF (Fig. 4).
Fig. 4. Expression of VEGF in GISTs with and without relapses in period from 1 till 3 years
Finally, the average expression of Ki-67 were 13.4 % in GISTs with relapses and 8.7 % 
in GISTs without them (U-test = 16; p ≤ 0.01).
4. Discussion
The data that we obtained in our study show that analysis of CD 117, DOG-1 and SMA ex-
pression is important for differential diagnosis of spindle cell GISTs. The first 2 markers are also 
recommended in protocol for GIST examination given by College of American pathology [12]. The 
analysis of SMA expression is important for differential diagnosis between spindle cell GISTs and 
leiomyomas [1, 5, 12]. Although numerous data talk about absence of SMA expression in GIST [1], 
some authors reported about occasional expression of SMA in some tumour cells in GISTs [13, 14]. 
Such an occasional expression in a few tumour cells we have seen in our study too. In our study, 
we also described focal expression of CD56 in epithelioid GISTs. The similar finding was reported 
in study of A. Agaymy and P. H. Wünsch, who said that focal expression of CD56 can be seen in 
50 % of epithelioid and only 7 % of spindled GISTs [15]. Epithelioid GISTs in our study demonstra-
ted weaker expression of CD117 compared with spindled GISTs, some other authors also said about 
such weak focal expression of CD117 in epithelioid gastric GISTs and mentioned that such group of 
tumours have PGFRA mutations [16, 17]. Especially for such subtype of tumors is recommended 
to perform IHC analysis with DOG-1, that is more sensitive for GISTs [12, 18]. In our study we saw 
that tumors with mild heterogenous CD117 expression demonstrated moderate or strong expression 
of DOG-1. Expression of CD34 was negative in epithelioid GISTs. This data is very similar to data 
given by WHO in last classification of digestive system tumors [1, 7, 19]. The CD34 expression in 
spindled GISTs was seen in 68.1 % of spindled GISTs in our study that not contradicted to different 
scientific data where this marker expressed approximately in 70 % of GISTs [12, 13].
Analysis of expression of such markers as p16ink4A, ki-67, VEGF and MMP-9 demon-
strated that expression of these markers were higher in GISTs that have relapses compared with 
GISTs without them. The expression of last 3 markers is widely described in different tumours 
and they are known as markers of aggressive behaviour. Different authors have shown that high 
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The high-level expression of p16ink4a in tumors is associated with aggressive subtypes of dis-
ease, and in certain clinical settings elevated p16ink4a expression is an important determinant 
for disease prognosis and therapeutic response [11, 20, 21]. F. Haller et al. in their article de-
scribed the cytoplasmic expression of p16ink4A as an independent factor of worse prognosis 
in GISTs [20]. All this data supports the hypothesis that these markers can be used as a prognos-
tic marker in GISTs too. But ancillary study of these markers and influence of other factors of 
GISTs progression are required.
Study limitations. The study of prognostic markers requires analysis of larger groups of 
GISTs to find cut-off levels of markers expression that will be helpful for given a more accu-
rate prognosis. 
Prospects for further research. The further study of different molecular-biological fea-
tures of GISTs will allow us to predict better behavior of these tumors and choose the best strategy 
of treatment for each patient.
5. Conclusions
We recommend using the following minimal panel of markers for differential diagnosis 
of spindled GISTs from other mesenchymal tumours of gastrointestinal tract: CD117, DOG-1 
and SMA, where the first markers will demonstrate the moderate or strong diffuse expression and 
SMA can be occasionally positive in some tumour cells.
The use of DOG-1 is crucial for differential diagnosis of epithelioid GISTs, because this 
group of tumours can demonstrate only weak focal expression of CD117 in some tumour cells. 
Additionally, in epithelioid GISTs can be used CD56 that can give focal positive reaction in some 
tumour cells.
Such markers as p16ink4A, Ki-67, VEGF and MMP-9 can be used as additional prognostic 
markers in GISTs.
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